Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD.
Urology. 2021 Apr;150:194-200. doi: 10.1016/j.urology.2020.05.009. Epub 2020 May 18.
To analyze inaccuracies in the news media reporting of the 2019 US Food and Drug Administration (FDA) ban on surgical mesh for transvaginal repair of pelvic organ prolapse (POP).
We queried the NexisUni media database for English-language news articles about "transvaginal mesh" or "FDA" published before and after the ban. Content analysis was based on discussion of the ban, indications for surgical mesh, and assessment of bias. We characterized public interest in transvaginal mesh using Google Trends.
Of 290 news articles reviewed, 42 articles were included for analysis. Public interest in transvaginal mesh increased 4-fold after the FDA announcement. While 15 articles (38%) accurately reported that mesh was used in both POP and incontinence repairs, a plurality (18, 43%) only described using mesh for POP. The majority (30, 71%) of articles did not specify that the FDA ban applied to only transvaginal repair of POP and not to incontinence. Despite multiple professional societies affirming the use of mesh for incontinence, only 2 (5%) articles cited these evidence-based recommendations. About half of the articles had an overtly biased tone; articles with an anti-mesh bias were significantly less likely to identify the mesh indications relevant to the ban (P <.01).
Seventy percent of news reports about the 2019 FDA ban on transvaginal mesh for POP failed to distinguish between the clinical indications for mesh impacted by the ban. The findings raise concern about patient perceptions of and future access to mesh surgery, regardless of indication.
分析 2019 年美国食品和药物管理局（FDA）禁止经阴道修复盆腔器官脱垂（POP）使用外科网片的新闻媒体报道中的不准确之处。
我们在 NexisUni 媒体数据库中查询了在禁令前后发布的关于“经阴道网片”或“FDA”的英文新闻文章。内容分析基于对禁令、外科网片适应证的讨论以及对偏见的评估。我们使用谷歌趋势来描述经阴道网片的公众兴趣。
在审查的 290 篇新闻文章中，有 42 篇文章被纳入分析。FDA 宣布后，公众对经阴道网片的兴趣增加了 4 倍。虽然有 15 篇文章（38%）准确报道了网片既用于 POP 又用于尿失禁修复，但多数（18 篇，43%）仅描述了用于 POP 的网片。大多数（30 篇，71%）文章没有具体说明 FDA 禁令仅适用于经阴道修复 POP，而不适用于尿失禁。尽管多个专业协会都肯定了网片在尿失禁中的应用，但只有 2 篇（5%）文章引用了这些基于证据的推荐。大约一半的文章带有明显的偏见语气；带有反网片偏见的文章明显不太可能确定与禁令相关的网片适应证（P<.01）。
70%的关于 2019 年 FDA 禁止经阴道网片治疗 POP 的新闻报道未能区分禁令所涉及的网片临床适应证。这些发现引起了人们对患者对网片手术的看法和未来获取的关注，无论适应证如何。
